The primary endpoint of the study was to determine whether the addition of Empliciti to Revlimid and low-dose dexamethasone would improve progression-free survival. Credit: KGH.

Bristol Myers Squibb’s (BMS) ELOQUENT-1 Phase III trial evaluating the Empliciti combination in patients with newly diagnosed, previously untreated multiple myeloma has failed to meet the primary endpoint of progression-free survival (PFS) in patients ineligible for transplant.

The randomised, open-label trial analysed combinations of Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ERd), versus Revlimid and dexamethasone alone (Rd) in the subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Empliciti is an immunostimulatory antibody that targets a cell-surface glycoprotein called Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7).

The company revealed that the addition of Empliciti did not find a statistically vital improvement in PFS in the final analysis.

Secondary endpoints of the ELOQUENT-1 Phase III trial were objective response rate and overall survival. The safety profile of ERd was observed to be generally consistent with the known profile of Empliciti plus Revlimid and dexamethasone.

Bristol Myers Squibb Hematology Global Clinical Development senior vice-president Noah Berkowitz said: “While we are disappointed that the ELOQUENT-1 trial did not meet its primary endpoint in these previously untreated, transplant-ineligible patients, the Empliciti, Revlimid and dexamethasone combination remains a standard treatment for patients with relapsed/refractory multiple myeloma, providing the potential for improved survival in this population of patients who are in need of additional treatment options.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Multiple myeloma is said to be an aggressive disease characterised by relapse and is prone to be refractory to several therapies.

BMS said that it will complete a full evaluation of the ELOQUENT-1 data and work with investigators to present the results at a future medical meeting.

The company is developing Empliciti with US biopharmaceutical company AbbVie.